OnProcess Exceeds All Financial Expectations for FY21-22 and Drives Forward on a Circular Mission
1.6.2022 15:00:00 EEST | Business Wire | Press release
OnProcess Technology, a global pioneer powering the world’s circular service value chains, today announced the results of its 2022 financial year to shareholders, reporting success across all four ‘pillars’ of the company’s strategy, and defining a new ‘digital first’ direction for the company.
From a financial perspective, OnProcess highlighted a very strong year, finishing well ahead of revenue expectations and EBITDA targets. It also reported a 109% growth in revenues from existing customers against the lowest churn rate for many years, and an increase in customer Net Promoter Score (NPS) to 57.6.
OnProcess also confirmed the closing of a substantial investment round which will be used to further boost the technology and product roadmap as well as developing new sales and marketing capabilities into new market sectors.
OnProcess also highlighted the development and launch of its flagship digital platform, OnProcess Agora™ during the financial year, along with the first new application built on it, Agora Recover™, aimed at digitalizing the returns process, improving customer experience and satisfaction levels, and setting the path towards more sustainable, circular service supply chains. OnProcess Agora now forms the basis of all new customer implementations and the new digitalization direction set by the company – a transformational approach that not only applies digital efficiency to its customers’ processes but entirely new ways of running those processes and delivering new end-customer experiences.
The company also revealed some of its plans for the new financial year 2022-23, highlighting new product offerings under development as well as expansion into new market segments. To help drive those product innovations, the company announced the appointment of its first Chief Product Officer. Other focus areas for FY23 would be to drive the continued adoption of the Agora platform from existing customer migrations as well as new customer and account growth. It also announced further investment in talent as well as cementing the company’s stance on diversity, equity, and inclusion (DEI) and a commitment around certain social responsibility initiatives on sustainability and circular economy metrics for the company as well as for its customers.
“I am immensely proud of what the OnProcess team has achieved this year and would like to thank all of them for their efforts in delivering what has been a very successful year for OnProcess,” said Oliver Lemanski, CEO of OnProcess. “We have surpassed every goal set against our transformational strategy and exceeded all financial targets, all with a backdrop of continued global uncertainty from the Covid-19 pandemic and supply chain challenges for our customers. A successful year by any measure, but perhaps even more importantly one that shows that our strategic path of a new ‘digital-first’ OnProcess, is indeed the right one.”
About OnProcess Technology , Inc.
OnProcess supplies technology and services that power the world’s circular service supply chains. Providing managed services and digital transformation expertise that streamlines processes, maximizes customer lifetime value, and improves ‘circular’ sustainability goals, OnProcess is a trusted advisor to many of the world’s leading computer, networking, med-tech, wireless, telecommunications, and IT companies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005162/en/
Contact information
Media:
Marta Marinova
OnProcess Technology, Inc.
mmarinova@onprocess.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom